Jubilant Life Sciences receives ANDA approvals for Mycophenolate Mofetil and Rizatriptan
Jubilant Life Sciences Ltd, an integrated Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval […]
Say something
Tags: Chemistry, europe, FDA Phase, Health/Medical/Pharmaceuticals, JUBILANT CADISTA PHARMACEUTICALS INC., Jubilant Generics Ltd., JUBILANT LIFE SCIENCES LIMITED, Maxalt, MERCK Kommanditgesellschaft auf Aktien, migraine, Mycophenolate Mofetil USP, Mycophenolic acid, Organic chemistry, Rizatriptan, Rizatriptan Tablets, treatment of migraine, Triptans, United States, US Food and Drug Administration, USD, XiAn Hex Life Sciences Co. Ltd.
Jubilant Acquires all Outstanding Shares of Cadista Holdings
Jubilant Life Sciences has completed tender offer to acquire all outstanding shares of Cadista Holdings Inc, thereby making the US-based […]
IFC extends $147-million loan to Jubilant Pharma
International Finance Corporation (IFC), a member of the World Bank is lending $147.5 million (around Rs.866 crore) to Jubilant Pharma […]
Jubilant Life Sciences Ltd announces financial results for the quarter
The Board of Jubilant Life Sciences Limited, an integrated pharmaceutical and life sciences company met today to approve financial results […]
-
-
Flipkart Health+ App Launched
06-04-2022
